65,437 trials
Kidney Neoplasms
Primary: Progression-Free Survival (PFS) — 6.7; 4.7 Months — p=<0.0001
Carcinoma, Renal Cell
Primary: Objective Response Rate (Percentage of Participants With Complete Response [CR] or Partial Response [PR]): Independent Review Committee Assessment — 50.0 percentage of…
Non Small Cell Lung Cancer
Primary: Participants Experiencing Dose Limiting Toxicity (DLT) — 0; 2 participants
Infections, Papillomavirus · Papillomavirus Vaccines
Primary: Number of Subjects With Persistent Infection (6-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18 and/or With Histopathologically-confirmed Cervical…
Adverse Effects
Primary: Completion Rate — 26 percentage of successful completers
Chronic Obstructive Pulmonary Disease · Pulmonary Emphysema
Primary: Forced Vital Capacity (FVC) — 1.5; 2.1 liters
Breast Cancer
Primary: Number of Participants With Objective Response (OR) — 8 participants
Coronary Artery Disease
Primary: Number of Patients Participating in Cardiac Rehabilitation Programs (CRPs)1-year Post Coronary Artery Bypass Grafting (CABG)Surgery in the Intervention and Control…
Primary Immune Deficiency Disorders (PIDD)
Primary: Rate of Serious Bacterial Infections (SBIs) Per Person-year on Treatment — 0.035 SBIs Per Total Person-Years
Muscle Strength Quantitative Trait Locus 1
Primary: Changes in Muscle Strength in the Contralateral Untrained Wrist Muscles — 44.1; 11.7 Newton meters
Neoplasms
Primary: Maximum Tolerated Dose (MTD) — NA; NA; NA; NA mg/kg
Sedentary Lifestyle
Primary: Change From Baseline Fibroblast Growth Factor 21 (FGF21) Acutely and at Two Weeks — 276.8; 460.8 ng/L — p=<0.001
Neoplasms
Primary: Single Dose: Maximum Observed Plasma Concentration (Cmax) — 20.732; 32.007; 53.123 ng/mL
Stomach Neoplasms · Advanced Gastric Cancer
Primary: Number of Participants With Cycle 1 Dose-limiting Toxicities (DLTs) — 3 participants
Respiratory Tract Infections
Primary: Incidence of Participants With Diarrhea by Parental Report — 18.0; 21.9 Percentage of participants — p=>.05